Secondary farnesoid X receptor (FXR) effects, in addition to vitamin D receptor (VDR) effects, were observed in the rat liver after treatment with 1␣,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ], the natural ligand of VDR, caused by increased bile acid absorption as a consequence of apical sodium-dependent bile acid transporter induction. To investigate whether the increased multidrug resistance protein 1 (Mdr1)/P-glycoprotein (P-gp) expression in the rat liver and kidney was caused by the VDR and not the FXR, we examined changes in Mdr1/P-gp expression in fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice after intraperitoneal dosing of vehicle versus 1,25(OH) 2 D 3 (0 or 2.5 g/kg every other day for 8 days). Renal and brain levels of Mdr1 mRNA and P-gp protein were significantly increased in both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice treated with 1,25(OH) 2 D 3 , confirming that Mdr1/ P-gp induction occurred independently of the FXR. Increased P-gp function was evident in 1,25(OH) 2 D 3 -treated fxr(ϩ/ϩ) mice given intravenous bolus doses of the P-gp probe, [
Introduction
P-glycoprotein (P-gp), the gene product of the multidrug resistance protein 1 (MDR1), is a 170-kDa membrane transporter and member of the ATP-binding cassette superfamily (Juliano and Ling, 1976) . P-gp functions as an ATP-powered drug efflux pump that interacts with numerous large, nonpolar, and weakly amphipathic compounds and cations of no apparent structural similarity. P-gp is highly expressed in many major organs and tissues in the body, including the intestine, liver, brain, kidney, colon, testes, and placenta (Cordon-Cardo et al., 1990) . For this reason, P-gp plays a critical role in drug absorption, distribution, and elimination and is recognized as an important target for drug-drug interactions (DDIs) (Yu, 1999) .
Over the last few decades, multiple nuclear receptors and transcription factors were found to regulate MDR1/P-gp expression (Reschly and Krasowski, 2006) . These include the pregnane X receptor (PXR) and the constitutive androstane receptor, commonly referred to as xenobiotic-sensing nuclear receptors. Transactivation of the mouse Mdr1 gene by the humanized PXR was observed to result in altered drug disposition in transgenic mice (Bauer et al., 2006) . The rodent Mdr1 or human MDR1 gene is also regulated by the farnesoid X receptor (FXR) (Landrier et al., 2006; Martin et al., 2008) , and the FXR ligand, chenodeoxycholic acid, increased MDR1 mRNA in HepG2 cells (Martin et al., 2008) . The vitamin D receptor (VDR) displays similar homology with PXR and constitutive androstane receptor (Reschly and Krasowski, 2006) and is another nuclear receptor that transactivates MDR1. 1␣, [1, 25(OH) 2 D 3 ], the natural, active ligand of VDR (Tanaka et al., 1973) , resulted in up-regulation of MDR1/P-gp expression in human colon carcinoma cell lines such as Caco-2, LS180, and LS174T cells (Aiba et al., 2005; Fan et al., 2009; Tachibana et al., 2009 ) and elevated P-gp levels in human airway epithelium-derived Caclu-3 cells (Patel et al., 2002) . These results are consistent with the existence of a vitamin D response element in the MDR1 gene (Saeki et al., 2008) .
In rats treated with 1,25(OH) 2 D 3 in vivo, VDR led to increases in both Mdr1a mRNA and P-gp protein in the liver and kidney (Chow et al., 2009 (Chow et al., , 2010 . Because of low levels of VDR in the rat liver (Gascon-Barré et al., 2003) , induction of Mdr1a was suspected to be a result of indirect FXR effects elicited by induction of the apical sodium-dependent bile acid transporter (ASBT) in the rat intestine, culminating in increased absorption of bile acids into the portal blood rather than from direct VDR effects. Upon entering the liver, bile acids, ligands of FXR, elicited hepatic FXR effects (Chow et al., 2009) . Inasmuch as MDR1/P-gp may also be induced by bile acids (Martin et al., 2008) , the increase in hepatic P-gp could be the consequence of both the direct VDR effects and/or indirect FXR effects on 1,25(OH) 2 D 3 treatment to the rat in vivo.
To determine whether regulation of Mdr1/P-gp was via the direct action of the VDR or indirectly via the FXR, we carried out the present study to examine Mdr1/P-gp changes in fxr(Ϫ/Ϫ) mice and compared the changes in gene expression with those for the wild-type fxr(ϩ/ϩ) mice after vehicle and 1,25(OH) 2 D 3 treatment. FXR effects become obviated in fxr(Ϫ/Ϫ) knockout mice; despite that, combined VDR and FXR effects persisted in fxr(ϩ/ϩ) wild-type mice in vivo. A protracted dosing regimen of 50 ng (2.5 g/kg) of 1,25(OH) 2 D 3 by intraperitoneal injection every other day for 8 days was chosen to lessen hypercalcemia (Chow et al., 2011) . Changes in protein and mRNA expression were first determined to rule out the contribution of FXR in the upregulation of Mdr1/P-gp in both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice. We further investigated the fate of intravenous administration of tritiated [ 3 H]digoxin, a P-gp probe, that is eliminated via excretion only in the mouse, to demonstrate changes in digoxin disposition caused by elevated P-gp after 1,25(OH) 2 D 3 treatment. In vivo tissue levels of [ 3 H]digoxin, which underwent enterohepatic recirculation and renal tubular reabsorption, in treated and untreated fxr(ϩ/ϩ) mice were fit to a physiologically based pharmacokinetic (PBPK) model to appraise the role of the VDR in altering P-gp function. Special attention was given to brain P-gp, the site of action of analgesics, antiepileptics, anticancer, and antiretroviral drugs, and in the heart, the site of action of digoxin.
Materials and Methods

Materials
1␣,25(OH) 2 D 3 was purchased in powder form from Sigma-Aldrich Canada (Mississauga, ON, Canada). The primary antibodies for Western blotting were obtained from various sources. Anti-Pgp, anti-GAPDH, and anti-Lamin B were from Abcam Inc. (Cambridge, MA); villin was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); and anti-VDR was from Thermo Fisher Scientific (Waltham, MA). cDNA synthesis and real-time PCR reagents were obtained from Applied Biosystems (Foster City, CA). [ 3 H]Digoxin (specific activity, 40 mCi/ mol) was purchased from PerkinElmer Life and Analytical Sciences (Walham, MA) and purified by HPLC to Ͼ99% radiochemical purity . All other consumable reagents, including unlabeled digoxin, were obtained from Sigma-Aldrich Canada and Thermo Fisher Scientific (Mississauga, ON, Canada).
Induction Studies with 1,25(OH) 2 D 3 in fxr(؉/؉) and fxr(؊/؊) Mice In Vivo
Both the male and female fxr(Ϫ/Ϫ) mice were kind gifts from Dr. Frank J. Gonzalez (National Institutes of Health, Bethesda, MD). The fxr(Ϫ/Ϫ) mice contained only the last exon of the FXR ligand binding domain and all of the 3Ј untranslated region of the FXR gene (Sinal et al., 2000) . The C57BL/6 pure strain male fxr(Ϫ/Ϫ) mice were genotyped using the following fxr primers: forward (wild-type allele), 5Ј-TCTCTTTAAGTGATGACGGGAATCT-3Ј; forward2 (null allele, 5Ј-GCTCTAAGGAGAGTCACTTGTGCA-3Ј; and reverse, 5Ј-GCATGCTCTGTTCATAAACGCCAT-3Ј, as described by Sinal et al. (2000) . Male wild-type [fxr(ϩ/ϩ)] and knockout [fxr(Ϫ/Ϫ)] mice (8 -12 weeks), bred in the animal facility at the University of Toronto, were given water and food ad libitum and maintained under a 12:12-h light and dark cycle in accordance with approved protocols. Mice were injected with 0 or 2.5 g/kg 1,25(OH) 2 D 3 in sterile corn oil intraperitoneally every other day for 8 days. The concentration of 1,25(OH) 2 D 3 in anhydrous ethanol was determined spectrophotometrically at 265 nm (UV-1700; Shimadzu Scientific Instruments, Columbia, MD), and the 1,25(OH) 2 D 3 solution was diluted in sterile corn oil (Sigma-Aldrich Canada) for injection (Chow et al., 2009 ). The alternate-day regimen was chosen because of the lessened hypercalcemia observed in comparison with those given doses in consecutive days (Chow et al., 2011) .
On the ninth day, mice were anesthetized with an intraperitoneal injection of ketamine and xylazine (150 and 10 mg/kg, respectively). After flushing of the mouse blood from the lower vena cava with 10 ml of ice-cold saline, the intestine, liver, brain, and kidneys were removed and placed on ice. The ileal segment, taken as 6 cm proximal to the ileocecal junction and known to consist of the highest abundance of P-gp (Stephens et al., 2001; Liu et al., 2006) , was used for protein and mRNA analyses. The ileum was flushed with physiologic saline solution containing 1 mM phenylmethylsulfonyl fluoride (PMSF) to eliminate feces, everted, and placed in the same saline solution containing PMSF before being scraped with a tissue scraper for the collection of enterocytes (Chow et al., 2009 ). The liver, brain, kidneys, and heart were weighed and reduced to small pieces. The scraped enterocytes and tissue pieces were snap-frozen with liquid nitrogen and stored at Ϫ80°C until further analyses. 33,000g for 60 min at 4°C. The crude membrane pellet was placed in the resuspension buffer. A unified procedure was used for preparation of the crude nuclear fraction. All tissues were homogenized in an identical fashion with the same homogenizing buffer (250 mM sucrose, 10 mM HEPES, and 10 mM Tris-HCl, pH 7.4) containing 1% protease inhibitor cocktail, and the homogenate was spun at 3000g wherein the resultant pellet was resuspended in a nuclear buffer (60 mM KCl, 15 mM NaCl, 5 mM MgCl 2 ⅐6H 2 O, 0.1 mM EGTA, 300 mM sucrose, 0.5 mM dithiothreitol, 0.1 mM PMSF, 300 mM sucrose, and 15 mM Trizma HCl, pH 7.4) containing 1% protease inhibitor cocktail. Protein concentration was measured by the Lowry method (Lowry et al., 1951) .
Western Blotting
For determination of the changes in VDR and P-gp protein levels among tissues, 20 to 80 g was used; linearity for the relative intensity was shown to exist for the different amounts of tissue used. The sample was loaded and separated by 7.5 and 10% SDS-polyacrylamide gels, respectively, for VDR and P-gp analyses and transferred onto nitrocellulose membranes (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK), as described by Chow et al. (2009) . The membrane was blocked with 5% (w/v) skim milk in Tris-buffered saline, pH 7.4, with 0.1% Tween 20 (TBS-T) (Sigma-Aldrich Canada) and washed three times with TBS-T before incubating it with the primary antibody solution (2% skim milk) overnight at 4°C. Thereafter, the membrane was washed three times with TBS-T and incubated with a secondary antibody (2% skim milk) at room temperature for 2 h. The membrane was washed three times, and then incubated with chemiluminescence reagents from GE Healthcare for visualization of the band intensity, quantified by scanning densitometry (National Institutes of Health Image software; http://rsb.info. nih.gov/nih-image/). Protein loading error was corrected by normalizing the target protein band against the protein band of the housekeeping gene: villin for intestinal samples, Lamin B for the comparison of VDR among tissues, and GAPDH for the same tissue type.
Quantitative Real-Time Polymerase Chain Reaction
The detailed procedure of RNA extraction has been described previously (Chow et al., 2009 ). For total RNA isolation, scraped enterocytes and other organ tissues were homogenized with TRIzol solution (50 -100 mg/ml) and extracted with the TRIzol extraction method (Sigma-Aldrich Canada) according to the manufacturer's protocol, with modifications. The RNA purity of each sample was checked by absorbance ratios of 260 nm/280 nm and 260 nm/230 nm (Ն1.7). The 1.5 g of total RNA was converted to cDNA. Real-time quantitative PCR was performed with the SYBR Green detection system (Applied Biosystems 7500 Real-Time PCR System; Applied Biosystems, Streetsville, ON, Canada). Information on the primer sequence is summarized in The digoxin study was performed with fxr(ϩ/ϩ) mice only (same as C57BL/6 pure) treated with vehicle (corn oil) or 2.5 g/kg (or 50 ng/mouse) of 1,25(OH) 2 D 3 given intraperitoneally every other day for 8 days. On the ninth day, each mouse received a bolus injection of 0.1 mg/kg digoxin and ϳ1.6 million dpm of [ 3 H]digoxin in ϳ100 l of filtered saline solution containing 1.5% propylene glycerol via the tail vein and was placed inside a glass beaker atop a piece of suspended aluminum wire mesh for separate collection of the feces and urine. Three to five mice were rendered unconscious in a carbon dioxide chamber and used for blood collection by cardiac puncture via a 1-ml syringe, which was prerinsed with heparin (1000 IU/ml). After flushing of blood with ice-cold saline, perfused into the lower vena cava, the liver, kidney, heart, brain, and small intestine were rapidly removed, weighed, snap-frozen in liquid nitrogen, and stored at Ϫ80°C for future analyses. The feces above the wire mesh were collected and pooled together with flushed luminal contents of the small intestine and colon with ice-cold saline into pretared 15-ml polyethylene tubes. The urine from the collection beaker was pooled, together with water rinses (twice with 1 ml of water).
[ 3 H]Digoxin Analyses
Blood samples (0.25 ml) were deproteinized upon addition of methanol 1:4 (v/v). The sample was mixed for 1 min and centrifuged at 14,000g for 10 min at 4°C, and 0.9 ml of the supernatant was removed for liquid scintillation counting. Varying known counts of [ 3 H]digoxin were added to blank blood (same volume as samples) and used as standards and processed under identical conditions for construction of a calibration curve in the determination of total radioactivity of [ 3 H]digoxin in blood samples. Likewise, the liver, kidney, heart, brain, and small intestine tissue were homogenized 1:3 (w/v) in saline solution, and 0.25 ml (tissue) or 1.2 ml (brain) of the homogenate was deproteinized with MeOH, 1:4 (v/v) while 1.0 to 4.8 ml was removed for liquid scintillation counting. Blank tissue homogenate samples, spiked with the appropriate aliquots of dpm for construction of calibration curves for each tissue, were processed according to the same deproteinization procedure. Counts in the fecal mixtures were estimated to denote the extents of biliary and luminal excretion; the contents were homogenized, and the radioactivity was extracted with ethyl acetate, 1:4 (v/v), after mixing (vortex) vigorously for 5 min and spun at 14,000g for 10 min at 4°C. An aliquot (0.95 ml) of the upper layer was removed for liquid scintillation counting. Again, standards of known dpm in fecal material were processed in an identical manner and used for the construction of the calibration curve. The total radioactivity in urine samples was determined directly by liquid scintillation counting.
The HPLC assay of Liu et al. (2006) was used to separate digoxin from its di-and mono-digitosoxides and the aglycone. The dpm in the deproteinized samples from blood, urine, feces, and tissue were separated by HPLC to resolve [ 3 H]digoxin from its metabolite . The supernatant was evaporated under nitrogen gas and then reconstituted with 100 l of methanol. The reconstituted residue was centrifuged, and 75 l of the supernatant was injected into the HPLC Shimadzu system as described by Liu et al. (2006) . Separation was achieved by a C18 reverse-phase column (Altech Associates, Deerfield, IL; 4.6 ϫ 250 mm, 10-m particle size) and a binary gradient consisting of water and acetonitrile, with an initial condition of 18% 
acetonitrile maintained at a flow rate of 1 ml/min, then increased to acetonitrile to 28% . The eluted fractions were collected at 1-min intervals and counted, and fractions of digoxin and its metabolites recovered in the sample were multiplied to the total count of the sample to arrive at individual dpm of digoxin and the metabolites. Results from HPLC revealed that, on average, unchanged [ 3 H]digoxin represented approximately 98% of the total radioactivity for all blood and tissue samples (data not shown). A previous report also showed that the metabolic clearance of digoxin in mice was only approximately 3% of total clearance (Kawahara et al., 1999) . Thus, the total radioactivity of the sample was taken to represent unchanged [ 3 H]digoxin.
Modeling and Fitting
Whole-Body Physiologically Based Pharmacokinetic Modeling. The concept of intestinal segregated flow was incorporated in the PBPK model (Cong et al., 2000; Liu et al., 2006) . In this model, a minor portion of the intestinal flow (5-30%) perfuses the enterocyte region, whereas the majority of flow perfuses the serosal region (remaining flow Ͼ70%) (Cong et al., 2000) . The model consists of tissue compartments that described digoxin concentrations in the blood (C B ), heart (C heart ), kidney (C K ), liver (C L ), enterocyte (C en ), and serosal (C s ) tissues of the small intestine, other tissues (C other ), brain tissue (C Br ) and blood of the brain (C Br,B ) (Fig. 1) . The volume and tissue to blood partition coefficient (tissue concentration/blood concentration) of each tissue compartment, denoted as V and K TB , respectively, are further qualified with the appropriate subscript for that tissue. The tissue/blood partition coefficient (K TB ) of digoxin for the small intestine, liver, kidney, and heart were obtained experimentally from the tissue/blood ratios toward the end of the study (close to 600 min). We recognize that the tissue/blood concentration ratio would underestimate the true partitioning ratio within eliminating organs (Khor et al., 1991; Chiba et al., 1998) . For the intestine, K TB,I or C I /C B,I (intestine tissue/blood leaving intestine) is assumed to be identical for both the enterocyte and serosal tissue. This is an oversimplication because K TB,I would not equal C en /C enb (ratio of the enterocyte tissue concentration relative to that in blood leaving the enterocyte) in view of the known luminal secretion by the Wholebody PBPK model with blood and tissue (brain tissue, brain blood, heart, kidney, liver, small intestine, and other tissue) compartments. K TB , Q, and V represent the tissue to blood partition coefficient, blood flow to organ, and the tissue volume, respectively; f Q is the fractional intestinal blood flow to the enterocyte region. CL in Br and CL ef Br are the influx and efflux intrinsic clearances into and out of the brain, respectively. Other tissue, brain, kidney, liver, and small intestine are denoted by other, Br, K, L, and I; CL int,sec,K , CL int,sec,L , and CL int,sec,I are the intrinsic secretory clearances for the kidney, liver, and small intestine, respectively; k a is absorption rate constant in the intestine. See the Appendix and Tables 3 and 4 jpet.aspetjournals.org P-gp. The estimate of K TB,I should be better estimated by C s /C sb (ratio of the serosal tissue concentration relative to that in blood leaving the serosal tissue because of lack of elimination), because the serosa represents the noneliminating tissue of the intestine. The distortion of K TB,I by luminal secretion should be low because the flow to the enterocyte region was low, rendering a flow-weighted average concentration in intestine that would be quite close to the true estimate, especially when luminal secretion is absent.
The intrinsic secretory clearances for the kidney, liver, small intestine, and brain efflux that are representative of P-gp activities are denoted as CL int,sec,K , CL int,sec,H , CL int,sec,I , and CL ef Br , respectively; CL in Br represents the digoxin uptake intrinsic clearance into the brain tissue. Biliary secretion (CL int,sec,H ) followed by reabsorption (rate constant, k a ) allows for the enterohepatic circulation of digoxin. For the kidney, the filtrated and secreted digoxin is prone to reabsorption, and the net excretion is modified by the fraction reabsorbed (FR) within the renal tubule, as described by Levy (1980) . The roles of urinary pH, the pK a of digoxin, and the urinary flow rate on digoxin reabsorption were not considered, and the extent of reabsorption was assumed to be the same for both the control and 1,25(OH) 2 D 3 -treated mice. The differential equations that relate to mass transfer across these organs/tissues are summarized in the Appendix.
Fitting. Fitting of the PBPK model to data from the vehicle control and 1,25(OH) 2 D 3 -treated fxr(ϩ/ϩ) mice was performed with the program Scientist (version 2.0; Micromath, St. Louis, MO). Appropriate weighting schemes (unity, 1/observation, and 1/observation 2 ) were used. Some parameters were fixed in the fitting procedure; these included the blood and tissue volumes (V) and organ flow rates (Q), unbound fraction of digoxin (f P and f B ), and blood/plasma concentration ratio (B/P). The tissue/blood partition coefficients (K TB ) of digoxin for the small intestine, liver, kidney, and heart were obtained experimentally from the tissue/blood ratios toward the end of the study (close to 600 min).
The first strategy was to estimate the parameters first with the control data. The blood, urine, feces, and tissue data for the small intestine, liver, kidney, brain, and heart in control mice were used in the fitting to obtain the tissue/blood partition coefficient of the lumped tissues K TB,other , k a , CL in Br , FR, the fractional intestinal flow entering the enterocyte region (f Q ), and the apparent intrinsic clearances. Because the unbound fractions of digoxin in the intestine, liver, kidney, and brain (f I , f L , f K , and f Br , respectively) were unknown, the fitted intrinsic secretory clearances (CL int,sec ) and efflux clearance (CL ef Br ) were expressed as the product of tissue unbound fraction in tissue and intrinsic secretory clearance (for example, the apparent renal intrinsic secretory clearance, CLЈ int,sec,K is expressed as f K CL int,sec,K ). With the assumption that f Q , K TB,other , k a , CL in Br , and FR were identical between control and treated mice, estimates obtained in the first fit were used to estimate the apparent intrinsic clearances of the treated mice in a subsequent fit. The second strategy was to use both sets of control and treated data in the same (or forced) fit to arrive at parameter estimates. In the fit, f Q , K TB,other , k a , CL in Br , and FR were again considered as common and unchanged parameters for both control and treated mice, and the apparent intrinsic secretory clearances of the small intestine, liver, and kidney, and efflux clearances of the brain (f Br CL ef Br ) were allowed to alter because of 1,25(OH) 2 D 3 treatment. The weighting of two or one/ observation 2 yielded the highest model selection criterion and lowest coefficient of variation (S.D./parameter value).
Statistical Analysis
Protein and mRNA data were expressed as mean Ϯ S.D. The two-tailed Student's t test was used to compare differences between the vehicle control and treatment groups. For mRNA and protein analyses, data for the vehicle-treated sample from the fxr(ϩ/ϩ) mouse were set as the control (value set as unity) and used for comparison with those of other control and treatment samples. A P value of less than 0.05 was viewed as significant.
Results
VDR and Mdr1/P-gp mRNA and Protein Expression in the Ileum, Liver, Kidney, and Brain of fxr(؉/؉) and fxr(؊/؊) Mice Distribution of VDR Protein Expression Among Tissues. With the anticipation that the abundance of VDR would vary among tissues, samples containing 50 g of total crude nuclear protein were analyzed to examine the distribution of VDR protein in the nuclear fractions in the ileum, liver, kidney, and brain of fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice (data not shown). Linearity was shown to exist within the protein concentration range. However, larger variations in GAPDH were found in comparison with those for Lamin B among different tissues after loading of the same amount of tissue protein (data not shown). Thus, VDR protein intensities among different tissues were normalized to Lamin B. VDR protein expression for the ileum and kidney in both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice was high and similar; whereas VDR protein expression was significantly less in the liver (29 -35% of ileum control) and even lower for the brain (13-27% of ileum control) of both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice. These results generally showed a lack of difference in VDR protein expression between the fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice.
Effect of 1,25(OH) 2 D 3 on VDR mRNA and Protein Expression on fxr(؉/؉) and fxr(؊/؊) Mice. Basal levels of VDR mRNA in the ileum, kidney, and brain were similar in both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice, whereas hepatic VDR mRNA in fxr(Ϫ/Ϫ) mice was three times higher that of fxr(ϩ/ϩ) mice ( Fig. 2A) . Upon 1,25(OH) 2 D 3 treatment, a significant increase in VDR mRNA and protein (ϳ3-fold) was observed for the kidney with 1,25(OH) 2 D 3 treatment for both the fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice (Fig. 2) , although there was a slightly lower VDR protein in the 1,25(OH) 2 D 3 -treated fxr(Ϫ/Ϫ) mouse brains compared with that of control fxr(Ϫ/Ϫ) mouse (Fig. 2B) . The reason for the latter was unknown.
Effects of 1,25(OH) 2 D 3 on Mdr1 mRNA and P-gp Protein Expression in Both fxr(؉/؉) and fxr(؊/؊) Mice. Levels of Mdr1 mRNA and P-gp protein expression in the ileum and liver of both the fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice remained unaltered with 1,25(OH) 2 D 3 treatment (Fig. 3) . In contrast, treatment of 1,25(OH) 2 D 3 led to increased Mdr1 mRNA and P-gp protein expression in the kidney and brain of both fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice (Fig. 3) , although the natural abundance of Mdr1 mRNA in the brain of fxr(Ϫ/Ϫ) mouse was considerably lower than that of the wild-type counterpart, the fxr(ϩ/ϩ) mouse (P Ͻ 0.05) (Fig. 3A) . (Fig. 4A) . The concentration of [ 3 H]digoxin was significantly lower in the 1,25(OH) 2 D 3 -treated group only at 360 min (6 h). The individual data points were averaged, and the mean blood values were used to calculate the area under the curve [AUC (03ϱ) ] by the trapezoidal rule and extrapolation of the last concentration over the terminal half-life (␤) ( Table 2 ). This AUC (03ϱ) value for digoxin in mice treated with 1,25(OH) 2 D 3 was only 76% of that of control mice. The apparent total body and renal clearances were increased by 34 and 74%, respectively, and the terminal half-life, decreased by 30% in the mice treated with 1,25(OH) 2 D 3 ( Table 2 ). The Vd area (CL total /␤) for both the control and treatment group remained relatively unchanged.
Effects of 1,25(OH)
The cumulative amounts of [ 3 H]digoxin excreted in urine at 600 min and feces were comparable (Fig. 4, B and C) . Amounts in urine in 1,25(OH) 2 D 3 -treated mice were higher than those in control mice at almost every sampling time subsequent to 30 min (P Ͻ 0.05), except at 360 min (Fig. 4B ), and were significantly higher (42.6 Ϯ 9.5 versus 27.0 Ϯ 5.6% dose) at 600 min. The cumulative fecal amounts of [ 3 H]digoxin in the 1,25(OH) 2 D 3 -treated group were increased only slightly compared with those of control mice (Fig. 4C) . The apparent renal clearance (Fig. 5A) , estimated as the slope upon plotting the cumulative amount of [ 3 H]digoxin excreted into urine versus blood AUC of 1,25(OH) 2 D 3 -treated mice (0.074 ml/min) was 74% higher than that of the control mice (0.0426 ml/min). Our control values were slightly lower than those estimated by others for the renal clearance (0.069 ml/ min) (Kawahara et al., 1999) and total clearance (0.083 ml/ min) of digoxin (Griffiths et al., 1984) . The filtration clearance, calculated as f P GFR [where f p is 0.78 (Davies and Morris, 1993; Kawahara et al., 1999) ], was 0.22 ml/min, a value much higher in relation to observed renal clearance (0.0426 ml/min), suggesting that reabsorption played a significant role in the net renal clearance of digoxin in mice.
The fecal (sum of net intestinal and biliary) clearance (0.0969 ml/min), estimated as the slope upon plotting the cumulative amount of [ 3 H]digoxin recovered into feces versus the blood AUC, was higher than the renal clearance of (Table 2) . 1,25(OH) 2 D 3 treatment increased the fecal clearance by 30% over the control group (0.0742 ml/min) (Fig.  5B) . Reabsorption of the biliarily and intestinally excreted digoxin followed by reabsorption in the intestine (enterohepatic recirculation) must have occurred. The possibility was also mentioned by Kawahara et al. (1999) , and this could have affected the estimate of the fecal secretary clearances, which were deviated from the slopes of Fig. 5B .
Tissue Distribution
Estimation of Area Under the Curves. The amounts of [
3 H]digoxin, normalized to per gram of tissue in the small intestine, liver, kidney, brain, and heart were plotted against time (Fig. 6) . Levels of digoxin in the small intestine, liver, kidney, and heart were generally similar, except for the brain. In both control and treated groups, [
3 H]digoxin levels in the small intestine, liver, kidney, and heart displayed instantaneous accumulation within the first few minutes, followed by a rapid decay by 10 min, then gradually decayed thereafter (Fig. 6, A, B, C, and E) . However, the peaks occurred slightly longer (ϳ100 min) in the brain. In the brain, levels of [ 3 H]digoxin in the treatment group were markedly lower than those of controls (Fig. 6D) . When the AUCs in the small intestine, liver, kidney, brain, heart, and blood, derived from observations on the amounts per gram of tissue, were estimated by the trapezoidal rule (Table 2) , an apparently lower AUC (0 -600 min) (23%) was found for the brain in the treatment group. The AUC (0 -600 min) for the small intestine, liver, kidney, and heart remained relatively unchanged for both groups (Table 2) .
Tissue to Blood AUC Versus Time Profile. The tissue partitioning coefficient of digoxin was estimated as the ratio of AUC (03t) of tissue normalized to that of blood AUC (03t) (Fig. 7) . In control mice, digoxin tissue/blood AUC ratios of 6.0, 2.5, 1.12, and 1.3 were reached at 600 min for the small intestine, liver, kidney, and heart, respectively (Fig. 7, A , B, C, and E), and treatment with 1,25(OH) 2 D 3 exerted only minimal effects on the tissue/blood AUC ratio. In the brain, a gradual rise in AUC ratio over time was observed for both treatment and control groups (Fig. 7D) . The ratio was con- a All data points were averaged to provide the mean, and the value was used for calculation; the blood AUC (03ϱ) was estimated by addition of AUC (03600 min) to AUC extrapolated to infinity or (C (600 min) / ␤), where ␤ is the terminal decay constant.
b Calculated as dose/AUC (03ϱ). c Average of literatures values for f p (0.78) and GFR (0.28 ml/min) from (Davies and Morris, 1993; Kawahara et al., 1999) . d Renal clearance, slope in Fig. 5A . e Fecal clearance, slope in Fig. 5B . f 0.693/␤ whereby ␤ was obtained upon regression of the three last data points of the averaged blood concentration. g Calculated as CL total /␤. h All data points were averaged to provide the mean, and the value was used for calculation; tissue AUC (03600 min) was calculated by the trapezoidal rule. sistently lower than unity in the brain and was reduced with 1,25(OH) 2 D 3 treatment. A plateau level was not reached for the brain to blood AUC ratio at 600 min (Fig. 7D ).
Whole-Body PBPK Modeling
For both types of fits, the blood, urine, feces, small intestine, liver, kidney, brain, and heart data were fit to the whole PBPK model (Fig. 1) with literature values of tissue volumes and blood flows (Table 3 ) and the observed tissue partition coefficients (K TB ) (from Fig. 7) . For the first of the sequential fits, f Q , K TB,other , CL in Br , k a , and FR were 0.185 Ϯ 0.082, 2.50 Ϯ 0.17, 0.00303 Ϯ 0.000491 ml/min, 0.00293 Ϯ 0.00076 min Ϫ1 , and 0.830 Ϯ 1.39, respectively, for the vehicle control group, and those values were assigned to estimate the apparent intrinsic clearances for the 1,25(OH) 2 D 3 treatment group. The composite fits revealed a higher [ 3 H]digoxin elimination from blood caused by an increased apparent renal intrinsic clearance f K CL int,sec,K (from 0.0323 Ϯ 2.12 to 0.188 Ϯ 0.027 ml/min) and a greater efflux from brain tissue, f Br CL ef Br (from 0.00228 Ϯ 0.00482 to 0.00329 Ϯ 0.00409 ml/min) for the 1,25(OH) 2 D 3 treatment group (Table 4) . The apparent renal secretory intrinsic clearance (f K CL int,sec,K ) after 1,25(OH) 2 D 3 treatment was 3.65-fold that of control, a value that correlated well to the level of P-gp induction [2.65-fold for fxr(ϩ/ϩ) mice] and less so to the change in apparent renal clearance (1.74-fold) (Fig. 5A) caused by the presence of filtration and the high degree of reabsorption of digoxin. The parameter estimated for intestinal (f I CL int,sec,I ) and hepatic (f H CL int,sec,H ) secretions via P-gp were similar between the control and treatment groups (0.0227 Ϯ 0.0085 versus 0.0225 Ϯ 0.0050 ml/min for the intestine and 0.0157 Ϯ 0.00125 versus 0.0152 Ϯ 0.0086 ml/min for the liver; Table 4 ). These estimates, even when summed (0.0384 to 0.0377 ml/ min), were low in comparison to the fecal clearances (0.074 and 0.097 ml/min) estimated from the slopes of Fig. 5B , suggesting that the unbound fractions f I and f H must be very low. The estimates suggest that P-gp activities for both intestinal and biliary excretion were relatively constant (Table  4) . Moreover, the fitted results showed that the weighting of 1/observation 2 yielded the highest model selection criterion (MSC) (Table 4), and lowest coefficient of variation (S.D./ parameter value).
Estimates from the simultaneous (force) fit were generally similar to those obtained from the sequential fits (Table 4) . The common parameters, f Q , K TB,other , CL in Br , k a , and FR, were estimated to be 0.158 Ϯ 0.347, 2.42 Ϯ 0.82, 0.000301 Ϯ 0.000389 ml/min, 0.00216 Ϯ 0.00162 min Ϫ1 , and 0.858 Ϯ 2.53, respectively (Table 4) . Increased apparent renal intrinsic clearance f K CL int,sec,K (from 0.074 Ϯ 5.34 to 0.255 Ϯ 0.029 ml/min) and greater efflux from the brain tissue, f Br CL ef Br (from 0.00230 Ϯ 0.00422 to 0.00337 Ϯ 0.00363 ml/min) were observed for the 1,25(OH) 2 D 3 treatment group (Table 4) . The apparent renal secretory intrinsic clearance (f K CL int,sec,K ) after 1,25(OH) 2 D 3 treatment was 3.45-fold that of control, a value that correlated to well to the level of P-gp induction (2.65-fold; Table 5 ) but less so to the change in renal clearance (1.74-fold) (Fig. 5A) . These changes were not exact matches because of the presence of filtration and high degree of reabsorption of digoxin. Simulations performed using the FR as 0.857 and f Q as 0.158 and parameters obtained with the simultaneous fit showed that the blood and kidney and brain concentrations were generally insensitive to a doubling in f K CL int,sec,K (varied from 0.074 ml/min to 1 ⁄2, 2, 3, and 5 times) (Fig. 8) . In contrast, for drugs whose FR approaches 0, changes in f K CL int,sec,K would significantly affect tissue levels and renal excretion (simulation not shown). The ratio for brain efflux was 1.47 times higher for the 1,25(OH) 2 D 3 treatment group, a value similar to that for Western blotting (1.8 times; Table 5 ). Values of the apparent f I CL int,sec,I and f H CL int,set,H were of similar magnitude (0.0168 to 0.0189 ml/min; Table 4 ) and were unchanged with 1,25(OH) 2 D 3 treatment, as also found from Western blotting (Table 5) . Again, their sum was much less than the apparent fecal clearances (0.074 and 0.097 ml/min), supporting the view that f I and f H must be very small. Overall, the fitted results showed that the weighting of 1/observation 2 yielded the highest MSC (Table 4 ) and lowest coefficient of variation (S.D./ parameter value).
In both types of fits, values of f Q (Table 4) were similar (0.185 and 0.158) to that found for the rat intestinal preparation (Cong et al., 2000; Liu et al., 2006) and less than 20% of the total flow, favoring the concept of segregated flow to the enterocyte (Cong et al., 2000) . Although the fitted f K -CL int,sec,K for the force fit was almost twice that for the sequential fits, the change caused by 1,25(OH) 2 D 3 , denoted as the ratio of the apparent intrinsic clearances, was similar (Table 4 ). In comparison, the force fit yielded higher coefficient of variations but a higher MSC (3.58), showing that this strategy was superior over that of the sequential fits. Moreover, when the traditional PBPK intestine model (Cong et al., 2000) was used, a slightly inferior fit with higher coefficients , and heart (E). For each data point, the average value of tissue AUC of vehicle or treatment group is normalized to the average value of blood AUC of the same group. The ratios are plotted against time. The tissue-to -blood partition coefficients of the small intestine, liver, kidney, and heart were estimated at the plateau phases of the plot. 
a Average of literature values from Davies and Morris (1993) and Kawahara et al. (1999) . 
Discussion
In this study, we have used both wild-type fxr(ϩ/ϩ) and knockout fxr(Ϫ/Ϫ) mice to discern whether regulation of Mdr1a/P-gp observed in the rat after 1,25(OH) 2 D 3 dosing was caused by the direct actions of the VDR or through indirect actions by the FXR (Chow et al., 2009 (Chow et al., , 2010 . We appraised whether the VDR played a direct role in the up-regulation of the Mdr1 gene in the mouse. We found that there existed different responses between rats and mice caused by species differences that could be the result of different regulatory responses from nuclear receptors. First, ASBT induction with 1,25(OH) 2 D 3 , although observable in the rat, is deemed nonexistent in the mouse because of the presence of liver receptor homolog 1 cis-acting element on the mouse ASBT promoter in the intestine that exerts a negative feedback on ASBT on FXR activation (Chen et al., 2003 . For this reason, the FXR effects are lessened in the mouse, and both ASBT mRNA and protein expression and portal bile acid concentrations were unchanged (data not shown). By contrast, the low levels of VDR present in the rat liver (GasconBarré et al., 2003; Chow et al., 2009 ) are unlikely to forge direct links between transactivation of the Mdr1 gene and the VDR. Rather, FXR effects are suspected to be operative, especially in rat liver because of the low VDR levels and increased portal bile acids concentrations (Chow et al., 2009 (Chow et al., , 2011 . Second, protein levels of VDR in the mouse liver are relatively higher than those in the rat liver (Chow et al., 2010) in comparison with the ileum, and, upon activation, VDR could potentially be exerting a greater direct effect on Mdr1/P-gp expression in the mouse liver in vivo. These perceived differences aptly explain the different VDR observations on changes in Mdr1/P-gp expression of the mouse and rat. There was no induction of ileal Mdr1/P-gp in our study, and a slight, but insignificant, increase in Mdr1 mRNA was observed in livers treated with 1,25(OH) 2 D 3 in fxr(ϩ/ϩ) mice but not fxr(Ϫ/Ϫ) mice (Fig. 3) ; therefore, the involvement of FXR in the regulation of hepatic Mdr1 in the rat cannot be ruled out. Our previous investigation had shown that intraperitoneal administration of 1,25(OH) 2 D 3 to rats did not elevate P-gp levels in the intestine (Chow et al., 2010) , although P-gp was increased in the liver (Chow et al., 2009) . The lack of induction of intestinal Mdr1 in both the mouse and rat despite the abundance of VDR could be caused by low levels of 1,25(OH) 2 D 3 reaching the intestine or the amount of 1,25(OH) 2 D 3 needed for activation (Chow et al., 2009 ).
Of significance is that VDR activation increased Mdr1 and P-gp expression in the kidneys and brains of both the fxr(ϩ/ϩ) and fxr(Ϫ/Ϫ) mice (Fig. 3) , and the mechanism of induction is independent of FXR. The induction of renal Mdr1/P-gp in 1,25(OH) 2 D 3 -treated mice led to increases in renal and total body clearances and lowered blood AUC (03ϱ) , and these shortened the elimination half-life (Table 2 ). The up-regulation of P-gp expression in the kidney is thus expected to exert a significant impact on the disposition of digoxin, a P-gp substrate that is primarily renally excreted in humans. However, the lower sensitivity of the renal clearance to changes in efflux P-gp activity was caused by the high fraction reabsorbed for digoxin ( Fig. 8 and Table 5 ). For other renally excreted compounds that are less reabsorbed, P-gp induction is expected to play a greater role in increasing the renal clearance. Increases in brain P-gp levels also led to lower brain accumulation ( Fig. 6D and Table 2 ) and lower brain/blood partitioning (Fig. 7D ) of digoxin even though VDR mRNA and protein expression in the murine brain was low. There was a clear decrease in the brain/blood AUC ratio of the treated group versus the control group between 60 to 600 min, and the decrease in ratio was the greatest at 600 min (29% decrease).
The induction caused by 1,25(OH) 2 D 3 on the up-regulation of the Mdr1 gene via the VDR was explained using PBPK modeling, which predicted the changes in digoxin disposition in different tissues as a result of increased P-gp activity in the kidney and brain after1,25(OH) 2 D 3 treatment in the mouse. The PBPK model accurately predicted the data pertaining to digoxin disposition in the blood, urine, feces, brain, liver, kidney, heart, and small intestine (Figs. 4 and 6) and provided an accurate description of the insignificant P-gp activity in the intestine and the less than expected effect on renal secretion caused by the high extent of digoxin reabsorption in the kidney (Fig. 8 and Tables 4 and 5 ). By contrast, the renal clearances of digoxin in humans (125 ml/min) and rats (1.25 ml/min) (Harrison and Gibaldi, 1977a,b) were slightly larger than, or comparable with, their corresponding filtration clearances [90 ml/min in humans and 0.80 ml/min in rats estimated from the literature (Steiness, 1974; Evans et al., 1990; Davies and Morris, 1993) ], suggesting that secretion in these species plays a major role in renal excretion. These observations point to species differences in renal excretion and indicate that a higher reabsorption of digoxin occurs in the murine kidney. This study demonstrates that 1,25(OH) 2 D 3 treatment increased P-gp levels in both the brain and kidney in mice. This observation leads one to consider treatment with 1,25(OH) 2 D 3 or the vitamin D analogs and a P-gp substrate drug would lead to increased renal clearance of drugs. The up-regulation of brain MDR1/P-gp by 1,25(OH) 2 D 3 would have a significant impact on drug disposition, cell homeostasis, and altered pharmacological and toxicological outcomes. Indeed, high doses of 1,25(OH) 2 D 3 and the vitamin D analogs have been used as a therapeutic class of drugs for the treatment of hyperparathyroidism, kidney diseases, and cancer (Masuda and Jones, 2006) . These treatments may have the potential to change transporters and enzyme expressions and alter drug disposition (Chow et al., 2009 (Chow et al., , 2010 (Chow et al., , 2011 . DDIs involving P-gp in the brain may be beneficial or detrimental. For example, vitamin D analogs given concomitantly with P-gp substrates targeting the brain will increase drug efflux from the tissue, rendering the drug ineffective. When 1,25(OH) 2 D 3 is used in combination with anticancer agents such as paclitaxel, a known P-gp substrate, to treat cancer (Masuda and Jones, 2006) , lower therapeutic effects may result in the brain. P-gp substrates targeting the brain include the antiretrovirals such as atazanavir, ritonavir, and jpet.aspetjournals.org saquinavir for HIV treatment, antipsychotics such as risperidone (Kim, 2002; Zastre et al., 2009) , antiepileptic drugs such as topiramate (Luna-Tortós et al., 2009) , or central nervous system drugs such as morphine (Groenendaal et al., 2007) , and all of these probably will be affected. On the other hand, increased P-gp activity may decrease brain concentration of a drug such as oseltamivir (Tamiflu), a drug used for influenza treatment, which is a P-gp substrate (Morimoto et al., 2008 ). An up-regulation of P-gp may decrease brain concentration of oseltamivir in this case.
In summary, the VDR can up-regulate P-gp expression in the kidney and brain in mouse in vivo independently of the FXR. Unequivocally, the induction of Mdr1/P-gp in the rat and mouse by the VDR has been translated to observations in human cell lines, and the intestinal P-gp may be further involved in DDIs. VDR activation of MDR1 mRNA and P-gp had been observed in human colonic cell lines (Aiba et al., 2005; Fan et al., 2009; Tachibana et al., 2009 ), a notion consistent with the existence of vitamin D response elements (Saeki et al., 2008) . As a result, it is highly likely that 1,25(OH) 2 D 3 treatment in combination with other therapeutic agents would cause significant DDIs. 
Authorship Contributions
Participated in research design
ϩ Q heart C heart K TB,heart Ϫ ͑Q Br ϩ Q K ϩ Q HV ϩ Q other ϩ Q heart ͒C B (A1)
In the brain tissue (Br) compartment: In the heart compartment:
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In other tissue compartments:
In the kidney compartment:
In the above equation, the arterial unbound plasma concentration equals f P C B /(B/P). The filtered and excreted components are reabsorbed according to the fraction reabsorbed, FR.
In the liver compartment, with segregated flows returning from the intestine:
where Q HV is the sum of Q HA and Q PV .
In the intestinal compartments of the small intestine: Enterocyte region:
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In the fecal compartment:
